Quantcast

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

Research paper by Matthias A. Oberli, Andreas M. Reichmuth, J. Robert Dorkin, Michael J. Mitchell, Owen S. Fenton, Ana Jaklenec, Daniel G. Anderson, Robert Langer, Daniel Blankschtein

Indexed on: 09 Dec '16Published on: 23 Nov '16Published in: Nano Letters



Abstract

The induction of a strong cytotoxic T cell response is an important prerequisite for successful immunotherapy against many viral diseases and tumors. Nucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. The intracellular delivery of mRNA vaccines to the cytosol of antigen presenting immune cells is still not sufficiently well understood. Here, we report on the development of a lipid nanoparticle formulation for the delivery of mRNA vaccines to induce a cytotoxic CD 8 T cell response. We show transfection of dendritic cells, macrophages, and neutrophils. The efficacy of the vaccine was tested in an aggressive B16F10 melanoma model. We found a strong CD 8 T cell activation after a single immunization. Treatment of B16F10 melanoma tumors with lipid nanoparticles containing mRNA coding for the tumor-associated antigens gp100 and TRP2 resulted in tumor shrinkage and extended the overall survival of the treated mice. The immune response can be further increased by the incorporation of the adjuvant LPS. In conclusion, the lipid nanoparticle formulation presented here is a promising vector for mRNA vaccine delivery, one that is capable of inducing a strong cytotoxic T cell response. Further optimization, including the incorporation of different adjuvants, will likely enhance the potency of the vaccine.

Figure 10.1021/acs.nanolett.6b03329.1.jpg
Figure 10.1021/acs.nanolett.6b03329.2.jpg
Figure 10.1021/acs.nanolett.6b03329.3.jpg
Figure 10.1021/acs.nanolett.6b03329.4.jpg
Figure 10.1021/acs.nanolett.6b03329.5.jpg
Figure 10.1021/acs.nanolett.6b03329.6.jpg